TY - JOUR T1 - The stage is set for a new trial end point in ALS JF - Journal of Neurology, Neurosurgery & Psychiatry JO - J Neurol Neurosurg Psychiatry SP - 117 LP - 117 DO - 10.1136/jnnp-2020-325158 VL - 92 IS - 2 AU - Christopher J McDermott Y1 - 2021/02/01 UR - http://jnnp.bmj.com/content/92/2/117.abstract N2 - Al-Chalabi et al report the findings of a post-hoc analysis of edaravone study 19 to explore the performance of two clinical staging systems.1 2 This interesting work is not intended to settle the efficacy debate around edaravone which requires further prospective studies but it does demonstrate that the information provided by the staging systems may compliment current outcome measures.The amyotrophic lateral sclerosis functional rating scale - revised (ALSFRS-R) is increasingly being chosen over survival as the primary outcome measure in trials of amyotrophic lateral sclerosis (ALS) to enable faster and smaller trials. This is strategy that is not without its pitfalls as the edaravone situation with patchy worldwide regulatory approval demonstrates; therefore, it is important that the clinical … ER -